52 Views | 42 Downloads
Jonathan C. Roberts, Bleeding & Clotting Disorders Institute, 427W. Northmoor Rd., Peoria, IL 61614, USA. Email: jroberts@ilbcdi.org
SAH and AO conceived the analysis proposal, which was then discussed and refined with JCR, LMM and RFS. IH extracted and analysed the medical claims data. All authors were involved in data interpretation and determining the focus and content of the publication. All authors reviewed and commented on manuscript drafts and approved the final draft for publication.
Data were obtained from the IQVIA PharMetrics Plus database. Analyses were undertaken by Charles River Associates, Boston, MA, including Imrran Halari and was funded by Baxalta US Inc., a member of the Takeda group of companies, Lexington, MA, USA. Medical writing support was provided by Mary Berrington, PhD, and Iain Patefield, MS, of Parexel, Hackensack, NJ, USA, and was funded by Baxalta US Inc., a member of the Takeda group of companies, Lexington, MA, USA.
JCR has acted as a paid consultant for CSL Behring, Hema Biologics, Takeda, Sanofi Genzyme, Novo Nordisk, Octapharma, Pfizer, Spark and uniQure; is on speaker bureaus for Takeda, Sanofi Genzyme, Novo Nordisk and Octapharma; and has received funding for research from Takeda not related to this study. LMM has received research funding from Bioverativ and consulting fees from Takeda, Spark, Sanofi Genzyme, Bayer, Hema biologics and CSL. IH is a current employee of Charles River Associates. SAH is an employee of Baxalta US Inc., a Takeda company and holds stock and/or stock options in Takeda. AO was an employee of Baxalta US Inc., a Takeda company at the time of the study and owns Takeda stock. RFS has acted as a paid consultant to Takeda and Octapharma and has received an investigator‐initiated grant from Takeda for the ATHN 9 study (natural history study in severe VWD).
This research was funded by Baxalta US Inc., a member of the Takeda group of companies, Lexington, MA, USA.
© 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.